Framingham (16.9%) and the European Hypertension Chart (31.3%). Reasons for not using risk tools included time constraints (60.8%), not being convinced of their utility (22.1%) and lack of knowledge (20.0%). a high percentage of physicians believed the algorithms have limitations (72.4%); 92.1% believed they lead to overlooking other risk factors and 69.3% believed they cannot be used to calculate risk in elderly patients. The most commonly used clinical guidelines were those from the ESC (CVD Prevention in Clinical Practice [56.3%] and Management of Arterial Hypertension [29.9%]) or from local authorities (17%). In total, 12.9% of physicians reported not using guidelines; reasons included the wide choice or uncertainty of which to use (47.5%), time constraints (33.7%), lack of knowledge (27.7%) and a perception that they are unrealistic (23.8%). CONCLUSIONS: Time constraints, perceived utility and inadequate knowledge were common factors limiting the use of cardiovascular risk evaluation tools and assessment guidelines. Better compliance with risk assessment tools may reduce the high proportion of patients with poorly managed cardiovascular risk factors. OBJECTIVES: The Adult Treatment Panel III guidelines suggest that the goal of lowdensity lipoprotein cholesterol (LDL-C) in patients with both cardiovascular disease and diabetes is <100 mg/dL. Many patients remain poorly controlled despite various interventions in primary care, including statin therapy and health behavior modifi cation. We evaluated the impact of adding a clinical pharmacist intervention to usual care on LDL-C control and treatment costs in diabetic cardiac patients.
PCV123 EPIDEMIOLOGICAL STUDY OF EUROPEAN CARDIOVASCULAR RISK PATIENTS: DISEASE PREVENTION AND MANAGEMENT IN USUAL DAILY PRACTICE-TURKISH RESULTS OF EURIKA STUDY
Abaci A Gazi University, Ankara-on behalf of EURIKA Study Group, Turkey OBJECTIVES: To assess management of cardiovascular risk factors (CVRF) in daily clinical practice and to identify areas of potential improvement in primary prevention of CVD. METHODS: A total 663 patients >50 years of age (59.4 ± 7.6 years; 47.2% males) with at least one additional CVRF and 67 physicians (mean age: 40.7 ± 8.6 years; 82.1% males) were included from Turkey in the multicentre, multinational, cross-sectional epidemiological EURIKA study (NCT00882336) conducted across Europe. Management and control of classical, emergent and psycho-social CVRF, use of CV risk assessment by the physicians as well as barriers for estimating and using global cardiovascular risk scores were identifi ed. RESULTS: Total CV risk assessment in Turkish patients was stated to be performed by 48.5% of the physicians mostly by chart (71.9%) and mainly for an advice on healthy lifestyle (84.4%) and to decide on antihypertensive (78.1%) or lipid-lowering treatment (75.0%). Time constraint for global CV risk evaluation was the main reason (73.5%) for the lack of assessment identifi ed by the physicians. a total of 514 patients (77.5%) were classifi ed to have high CV risk by the physicians using a local (7.6%) or the recent European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (ESC 2007) (80.0%). Although global cardiovascular risk was said to be under control in 75.5% of the patients, satisfying control of CV risk factors was evident in only 56.7% while the overall percentage of the patients who were aware of their CV risk was 69.5%. CONCLUSIONS: Apparently targets defi ned in guidelines are not suffi ciently met and there is clear need for better management of high risk patients. Development of better structured and more realistic, simple and credible national guidelines adapted to suit local medical and economic conditions should be encouraged.
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IMPACT OF REGIONAL MEASURES IN THE SALES OF THE RENIN-ANGIOTENSIN SYSTEM ANTAGONISTS IN SPAIN
Gimenez E, Garrido E, Lindner L, Sabater J, Vieta A IMS Health, Barcelona, Spain OBJECTIVES: To analyze the impact of regional measures in the sales of the reninangiotensin system antagonists in Spain. METHODS: Regional measures from each of the 17 Spanish Autonomous Regions (AR) were identifi ed by searching on health services' websites. a Regional Measurement Scale (RMS) in rational use of drugs (RUD) was constructed. Values ranged from 0 to 24 considering the number and the specifi city of the applied politics. The 2009 market share of the Angiotensin-II Receptor Antagonists (AIIRA) vs. Angiotensin-Converting Enzyme (ACE) inhibitors was analyzed. AR market shares and RMS correlations were calculated. Correlated AR Market shares were adjusted according to the values of RMS using a linear regression model for the AR with correlation between the RMS and the market shares. The decrease in market share on the AIIRA by RMS point was determined by the slope coeffi cient of the regression (β). RESULTS: Health plans, clinical guidelines, pharmacotherapeutic guides, health technology assessments and therapeutic newsletters, promoting the prescription of ACE inhibitors rather than AIIRA, were identifi ed. In 14 out of 17 AR, the correlation between the RMS and the market shares was statistically signifi cant (r = 0.55, p = 0.004). Of these, three AR scored 0, fi ve 1 to 10, four 10 to 20, and two 22 and 23 points respectively. a 0.52% decline in the market share AIIRA was observed for each point in the RMS. The maximum impact observed in the market share was 11.96%. Considering that the variability in the AIIRA market share was 24.1%, half of it was explainable by the establishment of RUD measures. CONCLU-SIONS: Results support the fact that not only the establishment of regional measures is important but also the way they are implemented. Interest in cardiovascular diseases (CVD) in patients with schizophrenia has recently become growing among psychiatrists due to its documented incremental mortality for these causes. Identifi cation of markers for such disorders seems, therefore, reasonable. Serum Protein-C-Reactive (PCR) levels have been determined as a marker of infl ammation in individuals with CVD and/or at high risk for developing it. However, it is unknown the role of this protein in schizophrenics. Thus, the goal of this research was to explore the use of PCR as a marker of infl ammation and CVD in patients with Schizophrenia. METHODS: A cross-sectional analysis of the BSA administrative claim database was conducted including all men and women, >18 years, with a schizophrenia spectrum disorders (by DSM-IV criteria) diagnosis. PCR measurement together with socio-demographics, evolution, medical history, 10-years CVD risk (Framingham equation) and biochemistry data was extracted for analysis. RESULTS: A total of 705 patients [53.0% men, 48.2 + 15.8 years (mean + SD), 5.9 + 3.2 years of evolution, 79.7% on atypical drugs] met criteria for analysis. Mean 10-year CVD risk was high; 11.9% + 5.7% and mean PCR levels were 2.6 + 2.5 mg/L with 30.4% showing values above normal's (>3 mg/L). Unadjusted PCR slightly correlated with CVD risk; r = 0.171, P < 0.001. After adjusting by age, sex, evolution, smoking and anti-infl ammatory drugs treatment, PCR was linearly associated with 10-year CVD risk stratifi ed by its level of risk (low, moderate, high/very high); respectively, 2.3 (95% CI: 2.1-2.5), 3.1 (2.6-3.5) and 3.7 (3.2-4.1) mg/L; F = 13.5, P < 0.001. Patients with known CVD showed also higher PCR levels; 3.7 (2.9-4.5) vs. 2.5 (2.4-2.7) mg/L, p = 0.008, and higher probability of values above normal's; Odds Ratio = 4.71 (2.01-11.04), P < 0.001. CONCLUSIONS: High PCR levels (above normals) were associated with both known CVD and high/very high 10-year risk of CVD event in patients with schizophrenia. Then, PCR might be a marker of infl ammation and CVD in this psychiatric disorder.
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PROTEIN-C-REACTIVE AS A MARKER OF INFLAMMATION AND CARDIOVASCULAR DISEASE IN PATIENTS WITH SCHIZOPHRENIA: A CROSS-SECTIONAL ANALYSIS OF A HEALTH CARE PROVIDER ADMINISTRATIVE CLAIM DATABASE
PCV126
USE OF PROTON PUMP INHIBITORS (PPIS) IN ACUTE CORONARY SYNDROME PATIENTS TREATED WITH CLOPIDOGREL IN GERMANY, FRANCE, AND THE UNITED KINGDOM
Mccollam P 1 , Nasuti P 2 , Rex J 2 , Gaskin M 2 1 Eli Lilly & Company, Indianapolis, IN, USA; 2 IMS Health, London, UK OBJECTIVES: There is controversy in the literature regarding the effects of concomitant use of proton-pump inhibitors (PPIs) potentially reducing the clinical effectiveness of clopidogrel. Also in question is whether the effect occurs with all PPIs or only omeprazole The purpose of this study is to assess the usage of PPIs in combination with clopidogrel in Acute Coronary Syndrome (ACS) patients in the primary care setting. METHODS: This was a retrospective study using IMS Disease Analyzer databases in France, Germany and the UK. These longitudinal patient databases provide information from continuing physician and patient interaction on consultations, diagnoses and treatments within primary care. RESULTS: From April 2008 to April 2009, 57% of post-ACS clopidogrel patients also had a PPI prescribed (France 13th Euro Abstracts A365 54% and Germany 45%). An overall increase in co-prescribing of clopidogrel and PPIs was observed in all countries from April 2006 to April 2009 except for France where omeprazole co-prescribing decreased in 2008-2009. The most frequently prescribed PPI in combination with clopidogrel was omeprazole in all three countries (58% in the UK, 36% in France and 65% in Germany) The second most frequently used PPI was lansoprazole in the UK (36%), pantoprazole in Germany (21%) and esomeprazole in France (28%). The proportion of clopidogrel patients who were co-prescribed lansoprazole was 36% in the UK and only 11% in France and 2% in Germany. CONCLUSIONS: Overall prescribing of PPIs with clopidogrel after ACS is common in the UK, France and Germany. Since the publication of the OCLA study in 2008 no decrease in concurrent prescribing of clopidogrel and omeprazole was observed except in France. Revisions of national guidelines and the clopidogrel label in 2009 may further affect prescribing of PPIs, and especially omeprazole, with clopidogrel in the future.
PCV127 INCREASING NURSE STAFFING LEVELS IN BELGIAN CARDIAC SURGERY CENTERS: A COST-EFFECTIVE PATIENT SAFETY INTERVENTION?
Van den Heede K 1 , Simoens S 2 , Vleugels A 1 , Sermeus W 1 1 Katholieke Universiteit Leuven, Leuven, Belgium; 2 K.U. Leuven, Leuven, Belgium OBJECTIVES: A previous study indicated that increasing nurse staffi ng levels in Belgian general cardiac postoperative nursing units was associated with lower mortality rates. The aim of this study is to conduct a cost-effectiveness analysis of increasing nurse staffi ng levels to the level of the 75 th percentile in Belgian general cardiac postoperative nursing units from a hospital perspective. METHODS: The intervention was an increase in the number of nursing hours per patient day to the 75 th percentile for nursing units staffed below that level. The comparator was a "do nothing" alternative. With effectiveness results being relatively stable over time, the change in reimbursement and price decreases have a substantial impact on initial cost-effectiveness considerations. The three-year GERSHWIN study (GERman Stent Health outcomes WIthin Normal practice) was designed to determine long-term clinical outcome and economic consequences of Sirolimus-eluting stents (SES) versus bare-metal stents BMS in the treatment of CAD from a societal prospective. Economic analysis resulted in an ICER of c29,868 per avoided major adverse coronary events (MACE) based on 2003 to 2005 prices. Due to substantial price reductions, a remodelling with current prices would increase applicability of results by decision-makers. METHODS: Complete intention-to-treat study data were valued and analyzed with 2009 prices for the main cost drivers (hospital case rate, incremental stent cost and generic clopidogrel price). Sensitivity analyses were conducted to evaluate the robustness of the results and included a low-and high-cost scenario. RESULTS: Initial hospitalization costs were c1157 higher per patient receiving SES, driven primarily by the incremental acquisition cost for SES compared BMS. Follow-up direct costs were similar in both groups of patients, however the indirect costs in SES patients were signifi cantly lower. Overall 36-month MACE-related costs were c283 not signifi cantly higher in the SES group (p = 0.62). The ICER based on 2009 cost data resulted in c5320 per MACE avoided. Variation of incremental SES prices between c650 and c750 showed no signifi cant impact. CONCLUSIONS: Incorporating updated cost data can drastically change the ICER generated from health services research projects. Modelling with current cost data is an essential contribution for iterative cost-benefi t assessment procedures.
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TELEHEALTH-EARLY EVALUATION FINDINGS
Beale S 1 , Tatlock S 1 , Wheeler K 2 , Ryan J 2 1 University of York, York, North Yorkshire, UK; 2 NHS, York, North Yorkshire, UK OBJECTIVES: NHS North Yorkshire and York commissioned York Health Economics Consortium to carry out an evaluation of their recent Telehealth pilot involving patients with long-term conditions. The fi ndings from the evaluation will be used to inform plans for the further rollout of Telehealth in North Yorkshire. METHODS: Three approaches were employed: a questionnaire was used to obtain details about the Telehealth experiences of users and their carers; Case Managers and Community Matrons with Telehealth patients on their caseloads were interviewed about referral criteria and the impact of Telehealth on their role and patient care; Health care resource use data were analyzed. Some caution should be used when generalizing fi ndings due to the small sample size and the specifi c characteristics of pilot Telehealth recipients. RESULTS: Forty-eight questionnaires were handed out and twenty returned (42%). Overall, respondents were happy with Telehealth (90%). Results showed that the installation process had been smooth (75%); individuals had received suffi cient tuition (95%); they were confi dent using the equipment (95%); and were happy with the service received from the monitoring centre (95%). Telehealth gave users peace of mind and helped them to manage their own health condition. However, a number of users had experienced technical issues (during installation and when taking daily measurements). Although there had been some teething problems, mainly in relation to the installation process and the monitoring system, clinicians were broadly supportive of Telehealth. There was a repeated view that individual patient characteristics needed to be taken into account when identifying patients who would benefi t from Telehealth. The impact of Telehealth on health care resource use was diffi cult to determine within the eight month timescale of the pilot. CONCLUSIONS: Telehealth gives users peace of mind and helps them manage their health; however, its impact on health care resource use is still unclear.
PCV130 PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2008-2009: BASELINE RESULTS FOR AUSTRIA FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II)
Ammer M 1 , Paget MA 2 , Hronkova M 3 , Norrbacka K 4 , Eber B 1 1 Klinikum der Kreuzschwestern Wels, Wels, Austria; 2 Lilly France S.A., Suresnes Cedex, France; 3 Eli Lilly & Company, Vienna, Austria; 4 Eli Lilly & Company, Vantaa, Finland OBJECTIVES: This analysis aims to explore management of acute coronary syndromes (ACS) from acute event to hospital discharge in Austria, and to measure Quality of Life (QoL) at discharge. METHODS: This 12-month international, prospective, observational study recruited ACS patients in selected hospitals undergoing percutaneous coronary intervention (PCI), April 2008-March 2009, capturing practice patterns, resource use and QoL. RESULTS: A total of 148 ACS-PCI patients (out of the 152 recruited) were eligible: median age 60 yrs (IQR 51-69), median weight 80 kg (IQR 70-89), 20% female, 28% Type II diabetics, and 17% prior myocardial infarction (MI). Index diagnosis was: unstable angina or non-ST-elevation MI (UA/ NSTEMI)-44% and ST-elevation MI (STEMI)-56%. Almost all patients (96%) received stents: 28% bare metal stents only, 70% drug eluting stents only and 2% both. Time from start of ACS symptoms to PCI was ≤3 days in 86% of UA/NSTEMI patients and ≤1 day in 98% of STEMI patients. Oral antiplatelet medications with loading dose (LD) used: aspirin-97% and clopidogrel-91%. Clopidogrel LD was administered in the ambulance-9%, previous hospital-10%, emergency room-41%, CCU or ICU-31%, catheterization lab-5%, or other ward-5%. LD was administered between 6 hours before to 6 hours after PCI in 82% of cases. The fi rst clopidogrel LD was 600 mg in 85% and 300 mg in 10% of cases and in-hospital maintenance dose was 75 mg in 97%. At time of hospital discharge, 97% of the discharged patients were prescribed clopidogrel (discharge dose 75 mg for all patients except one). QoL in discharged patients was good: median EQ-5D health state index at 1.00 (IQR 0.81-1.00). CONCLUSIONS: These real life data refl ect treatment patterns among ACS patients managed by PCI in selected hospitals in Austria in 2008-2009. Timing and place of loading of antiplatelet agents differ. The QoL of patients at discharge was high.
